Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

OrbiMed

Access Biotechnology

Bain Capital Life Sciences

Novo Holdings

Janus Henderson Investors

Rock Springs Capital

5AM Ventures

Arix Bioscience

Atlas Venture

Nantahala Capital Management

Disc Medicine

NASDAQ:IRON

Disc Medicine, Inc.

Last Close

43.92

26/07 20:00

Market Cap

1.36B

Beta: -

Volume Today

207.34K

Avg: 239.90K

PE Ratio

−23.00

PFCF: −24.49

Institutional trades

Institutional Ownership

Current holdings institutionals